TubeFolio - AI YouTube Video Summarizer & Media Insights

Summary

Parkev provides an update on United Health, noting its strong performance in 2026. He attributes this recovery to management's strategic response to the margin collapse seen in previous years, where operating margins dropped from 8.1% to 4.2%. By increasing premiums and exiting unprofitable markets, the company has "right-sized" its operations, which investors have rewarded. He notes recent headwinds such as a lawsuit in Arizona and Berkshire Hathaway selling its stake, but maintains that the core business remains solid and offers a hedge against macroeconomic volatility.

United Health (UNH): Parkev maintains a buy rating with a calculated fair value of $469 per share, representing upside from the current price of approximately $408. He highlights the stock's role as a portfolio diversifier, particularly for those heavily invested in the AI sector, due to its low correlation with macroeconomic cycles. Although he is less excited than he was when the stock was near its 52-week low of $234, he believes the current forward P/E of 21.5 is still reasonable for long-term, low-risk investors.

Mentioned Stocks

UNH

Sentiment: BUYAction: RECOMMENDED

Reasoning: Parkev maintains a buy rating because his discounted cash flow model yields a fair value of $469, which is significantly higher than the current market price of $408. He notes that management has successfully navigated a margin collapse by raising prices and exiting unprofitable segments. Despite being near its 52-week high of $416 and facing a lawsuit in Arizona, he views it as a high-quality, low-volatility diversifier for portfolios currently dominated by AI trades.

Loading chart...